Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2011

8.	NET LOSS PER SHARE

Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Potential common stock equivalents consist of stock options, warrants and convertible preferred stock and accumulated dividends. Since the Company has a net loss for the three and nine months ended September 30, 2011, the inclusion of common stock equivalents in the computation would be antidilutive. Accordingly, basic and diluted net loss per share are the same for the three and nine months ended September 30, 2011.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

									Cumulative
									Development-
									Stage Period from
									November 7, 2002
									(inception)
	Three Months Ended				Nine Months Ended				through
	September 30,				September 30,				September 30,
	2011		2010		2011		2010		2011
Convertible debt		—		3,547,198		—		3,547,198		—

Warrants		7,327,322		—		7,327,322		—		7,327,322

Stock options		3,632,638		775,853		3,632,638		775,853		3,632,638